基层PCI术后冠心病患者服用抗血小板药物依从性调查分析  

Compliance of Antiplatelet After PCI with Grassroots coronary heart Disease

作　　者：周树军[1] 王振娟[1] 张立强[1] 王云梅[1] 宗文仓[1] 孔令军[1] 娄志刚[1] 

机构地区：[1]玉田县医院药剂科,心内科,河北玉田064100

出　　处：《四川医学》2016年第4期444-446,共3页Sichuan Medical Journal

摘　　要：目的探讨基层冠心病患者经皮冠状动脉介入治疗术(PCI)后双联抗血小板药物不同依从性对临床预后的影响。方法选取2011至2014年在我院被确诊为冠心病并行PCI的患者180例进行随访,由临床药师负责,详细记录每例患者用药情况及心脑血管不良事件(死亡、心肌梗死、卒中、再次血运重建)发生情况。根据随访抗血小板用药情况,将患者分依从性好(n=138)及依从性差(n=42)两组,比较两组患者心脏主要不良事件(MACE)发生情况。结果两组患者的基线特征、临床特征及治疗情况结果等一般资料比较差异均无统计学意义(P>0.05)。依从性好组主要不良事件及因心血管事件再入院的发生率低于依从性差服药组,差异有统计学意义(P<0.05)。结论双联抗血小板药物依从性好能减少心血管事件的发生,基层冠心病患者PCI术后双联抗血小板药物依从性有待提高。Objective To evaluate the clinical prognosis of different compliance dual antiplatelt therapy after percutaneous coronary intervention（ PCI） with grassroots coronary heart disease. Methods The study enrolled 180 patients who received drug-eluting stents from 2011 to 2014,Responsible for clinical pharmacists,each patient medications and cardiovascular adverse events detailed record（ death、myocardial infarction、stroke、revascularization） Occurrence. according to followup antiplatelet drug use,Patients were divided into Continuous treatment group（ n = 138） and poor compliance group（ n = 42）,Comparison of two groups of major adverse cardiac events（ MACE） incidence. Results Baseline characteristics of the two groups of patients,the clinical features and treatment results and other general information was no significant difference（ P〈0. 05）. Continuous treatment group of major adverse events and readmissions due to cardiovascular events were significantly lower than poor compliance group,the difference was statistically significan（ P〈0. 05）. Conclusion Dual antiplatelet drugs and better compliance can reduce the incidence of cardiovascular events,Grassroots coronary heart disease patients after PCI dual antiplatelet medication compliance needs to be improved.

关 键 词：抗血小板药物 经皮冠状动脉介入治疗术 心血管事件 冠心病 

分 类 号：R541.4[医药卫生—心血管疾病]